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A 39-year-old female experienced dyspnea on exertion for eight months. Chest CT demonstrated ﬁndings
of Lymphangioleiomyomatosis (LAM), including diffuse thin-walled cystic lesions. A surgical lung biopsy
revealed human melanoma black-45-positive cell inﬁltration and aggregation, resulting in a diagnosis of
sporadic LAM without tuberous sclerosis complex. Pelvic MRI showed two large tumors, one of which
was in the myometrium and the other was in the retroperitoneal space. Because we were not able to
exclude the presence of malignant tumors using MR imaging, the tumors were surgically resected. The
histopathology demonstrated the resected tumors to be composed of LAM cells. The patient's symptoms
worsened, and sirolimus was administered, which improved the dyspnea and pulmonary function. The
adverse effect was mild liver damage. Following the initiation of treatment with sirolimus, transient
elevation of the serum KL-6 level was detected without interstitial pneumonia. This LAM case compli-
cated with large uterine and retroperitoneal tumors was successfully treated with surgical resection and
sirolimus.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lymphangioleiomyomatosis (LAM) is a rare, multiorgan disor-
der characterized by the proliferation of smooth muscle-like cells
(LAM cells) primarily in the lungs and axial lymph nodes [1e6]
Sporadic LAM is known to exclusively affect young females of
reproductive age, with clinical manifestations such as progressive
dyspnea on exertion, recurrent pneumothorax, hemoptysis,
chylous pleural effusion and ascites [1,2]. Extrapulmonary
involvement, including that of the kidneys and pelvic organs, is a
common ﬁnding in patients with LAM; however, large uterine tu-
mors are extremely rare. Although there is no conventional treat-
ment, recent progress in research regarding the molecular
pathogenesis of LAM has identiﬁed TSC gene abnormalities [7,8],
indicating the participation of the mammalian target of rapamycin
(mTOR) signaling pathway in the proliferation of LAM cells [9] and
the potential for therapeutic approaches using mTOR inhibition.inato ward, Tokyo 105-8461,
Ltd. This is an open access article uWe experienced a case of sporadic LAM complicated with large
uterine and retroperitoneal tumors that were treated with a sur-
gical resection.2. Case presentation
A 39-year-old Japanese female presented with a complaint of
dyspnea on exertion that began eight months previously. Due to
worsening of her symptoms, she consulted a general physician ﬁve
months prior to visiting our department and was diagnosed with
bronchial asthma. Inhaled corticosteroids (ICS) and a long-acting
beta agonist (LABA) were initially introduced, without any
apparent improvements in symptoms. The patient had no past
medical history or smoking habits. A physical examination
demonstrated no abnormal ﬁndings. In the laboratory ﬁndings
obtained at the ﬁrst visit, hypergammaglobulinemia and a mildly
increased KL-6 level were observed. A blood gas analysis demon-
strated hypoxemia (Table 1), and a pulmonary function test showed
a moderate obstructive abnormality (FEV1%: 56.6%, %FEV1: 82.2%)
with a reduced diffusing capacity of the lung for carbon monoxide
(DLCO) (%DLCO: 41.2%).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Laboratory data.
CBC Biochemistry Immunochemistry
WBC 5300/ml AST 17 IU/l CEA 1.4 ng/ml
Neu. 57.9% ALT 8 IU/l SCC 1.2 ng/ml
Ly. 34.1% LDH 186 IU/l CA125 38 U/ml
Mo. 5.4% ChE 265 IU/l CA19-9 <1 U/ml
Eo. 1.9% T.Bil 0.5 mg/dl CA15-3 24 U/ml
Ba. 0.7% ALP 160 IU/l CA72-4 3 U/ml
RBC 5.14  106/ml g-GTP 14 IU/l NSE 11.3 ng/ml
Hb 13.9 g/dl TP 8.2 g/dl AFP 8 ng/ml
Ht 42.2% Alb 4.4 g/dl KL-6 506 U/ml
Plt 275  103/ml BUN 12 mg/dl
Cr 0.78 mg/dl Blood gas analysis(room
air)
ESR1h 24 mm Na 139 mmol/l pH 7.448
PT 100< % K 3.7 mmol/l PaO2 75.2 Torr
APTT 36.1 s Cl 107 mmol/l PaCO2 28.1 Torr
Fbg 321 mg/dl Ca 8.7 mg/dl HCO3- 19.2 mmol/l
CRP <0.04 mg/dl BE 3.3 mmol/l
SaO2 96%
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mild hyperinﬂation. Chest CT demonstrated diffusely distributed
small cystic lesions, reticular opacity and micronodular lesions
(Fig. 1A, B). These CT ﬁndings were suspicious to be LAM with
lymphatic edema; hence, a histopathological evaluation was
required to make a precise diagnosis.Fig. 1. Chest CT and pelvic MRI. A and B. Chest CT demonstrates diffusely distributed small cy
MRI show two large tumors, one of which (arrow) is located in the myometrium and the othe
that the two tumors have different patterns. The retroperitoneal tumor(arrowhead) is high
(arrow) in the myometrium of the uterus (asterisk) with a very strong contrasting effect.A lung biopsy specimen exhibited airspace dilatation with a-
smooth muscle actin (aSMA) and human melanoma black (HMB)-
45-positive smooth muscle-like cell (LAM cell) inﬁltration and ag-
gregation. The immunohistochemical examination of the LAM cells
was positive for both estrogen and progesterone receptors(ER, PR,
respectively) (Fig. 2AeF). No multifocal micronodular pneumocyte
hyperplasia (MMPH) lesions were observed in the specimen. Due to
the absence of typical manifestations, which is consistent with the
diagnostic criteria [10], and absence of family history of tuberous
sclerosis complex (TSC), the patient was diagnosed with sporadic
LAM.
Transabdominal and transvaginal ultrasound examinations
showed a suspected leiomyoma of the uterus, but during systemic
surveillance, pelvic MR imaging showed two large tumors with a
very strong contrasting effect in the myometrium of the uterine
corpus and retroperitoneal space (Fig. 1CeE). The CT of the
abdomen shows paraaortic lymphnodes (not shown). There was a
low possibility of leiomyoma due to the very strong contrasting
effect in the early phase on MR imaging. Hence the proposed dif-
ferential diagnoses were malignant tumor with hypervascularity
and uterine LAM lesion. However, there was no report about large
tumor to be composed of LAM cells in the myometrium. We dis-
cussed with gynecologists about non-surgical modality of treat-
ments for these lesions, wewere not able to exclude the presence of
malignant tumors with rapid growing on MR imaging and thus the
tumors were surgically resected. Total hysterectomy with bilateral
salpingo-oophorectomy (BSO) was performed due to bleeding and
tumor adhesion to the pelvic wall.stic lesions with reticular opacity. C and D. T2-weighted (C) and diffusion-weighted (D)
r (arrowhead) is located adjacent to the pelvic wall. The diffusion-weighted MRI reveals
er intensity than the uterine tumor. E. A sagittal section of pelvic MRI shows a tumor
Fig. 2. Histopathological ﬁndings of the surgical biopsy of the lung. A and B. Hematoxylin-Eosin staining of the lung biopsy samples shows diffusely distributed small cystic lesions.
Some cyst walls exhibit the accumulation of spindle-shaped cells. (B: 100). CeF. Immunohistochemistry demonstrates positive staining for aSMA, HMB45, estrogen receptor (ER)
and D2-40. (C and F: 100, D and E: 400).
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T. Numata et al. / Respiratory Medicine Case Reports 15 (2015) 71e7674The size of tumor in the myometrium of the uterine corpus was
45  45  25 mm, while that of the retroperitoneal tumor was
70  60  35 mm (Fig. 3A). Macroscopically, well-circumscribed,
yellowish and fragile tumors with cleft-like lesions were observed
fromthemyometriumof theuterine corpus to the serousmembrane
borderline (Fig. 3B). The histopathological evaluation demonstrated
the uterine and retroperitoneal tumors to be composed of aSMAand
HMB-45-positive spindle-shaped cell aggregation accompanied byFig. 3. Histopathological ﬁndings of the resected uterine and retroperitoneal tumors. A. A gro
tumor is in the right posterior wall of the uterus (arrow). The surface of the retroperitoneal tu
D. High magniﬁcation view of the uterine tumor (H-E (C) and D2-40 (D) staining). (100).
staining. There are LAM cell clusters in the myometrium and slit-like lesions (D2-40-posit
uterine tumor showing LAM cell inﬁltration in fat tissue (H-E (G: 200) and D2-40 (H: 40
positive lymphatic endothelial cells. LCC is composed by LAM cells with HMB-45 positive st
cell inﬁltration (ER, PR, HMB45 and aSMA staining, 100). N, O, P and Q. Low magniﬁcation
aSMA staining, 100).angiogenesis and lymphangiogenesis. These spindle-shaped cells
were partially positive by ER and PR staining. The existence of
lymphatic vessels was revealed by D2-40 staining. Accordingly,
these tumors were diagnosed as uterine and retroperitoneal LAM
lesions (Fig. 3CeQ). The histopathological ﬁndings of the retroper-
itoneal tumor correspond to the ﬁndings shown in uterine tumor.
Simultaneous ICS/LABA and tiotropium inhalation was started
for the treatment of dyspnea on exertion; however, no apparentss examination shows the uterine tumor resected via total hysterectomy with BSO. The
mor is rugged (inset). B. Low magniﬁcation view of the uterine tumor (H-E stain). C and
E and F. High magniﬁcation view of the myometrium showing H-E (E) and D2-40 (F)
ive) which mean lymphatic vessels. (100). G and H. High magniﬁcation view of the
0) staining). I. High magniﬁcation view of LAM cell cluster（LCC） enveloped by D2-40
aining(inset). J, K, L and M. Low magniﬁcation view of the uterine tumor showing LAM
view of the retroperitoneal tumor showing LAM cell inﬁltration (ER, PR, HMB-45 and
T. Numata et al. / Respiratory Medicine Case Reports 15 (2015) 71e76 75improvements were observed. Severe oxygen desaturation was
noted during a 6-min walking test, and home oxygen therapy was
initiated. Total hysterectomy with BSO improved the slope of the
forced expiratory volume in 1 s (FEV1) from 130 ml per month to
14 ml per month, suggesting a pseudomenopause effect induced by
BSO. In spite of the improvement in the patient's pulmonary
function, progressive worsening of dyspnea with deterioration of
activities of daily living was observed. Furthermore, the LAM his-
tologic score (LHS), a prognostic predictor [11], was class 3, thus
suggesting an unfavorable prognosis. Therefore, after obtaining
informed consent, treatment with sirolimus (1 mg/day), an mTOR
inhibitor, was initiated. After 10 months of sirolimus therapy, the
FEV1 increased from 1.8 L to 2.45 L, with a marked improvement in
the patient's respiratory symptoms. Because drug-induced liver
damage occurred, the sirolimus treatment was interrupted for
three months, resulting in a worsening of the FEV1 slope to with
200 ml per month. A reduced dose of sirolimus was administered
following an improvement in the liver damage. As a consequence,
the dyspnea and FEV1 slope recovered (Fig. 4).
Following the initiation of sirolimus treatment, mild elevation of
the serum KL-6 level from 437 to 1126 (U/ml) was detected;
however, serial high-resolution chest CT scans, which were per-
formed every six month, demonstrated no apparent development
of interstitial lung disease. Subsequently, the interruption and dose
reduction of sirolimus spontaneously decreased the serum KL-6
level. There are no recurrence of the tumors and no enlargement
of paraaortic lymphnodes.
3. Discussion
We experienced a case of sporadic LAM complicated with large
uterine and retroperitoneal tumors. Treatment with BSO and sub-
sequent sirolimus efﬁciently controlled the decline in the patient's
pulmonary function and the regrowth of these tumors during the
observation period. The recent identiﬁcation of a tuberous sclerosis
complex gene, TSC1/2, has improved understanding of the molec-
ular pathogenesis of LAM [7,8]. TSC1/2 gene abnormalities induceFig. 4. Clinical course Bronchodilators were initially introduced without any improvements i
with bilateral salpingo-oophorectomy (BSO) slightly reduced the decline in FEV1. However,
sirolimus was initiated. An apparent improvement in the FEV1 was observed following the in
been noted. The serum KL-6 level ﬂuctuated during the sirolimus treatment.LAM cell proliferation via the activation of mTOR; thus, mTOR in-
hibitors have been proposed to be effective treatment modalities.
Indeed, the results of the recent multicenter international lym-
phangioleiomyomatosis efﬁcacy and safety of sirolimus (MILES)
phase III trial demonstrated that sirolimus therapy signiﬁcantly
stabilizes declines in the pulmonary function (FEV1 slope) and is
associated with improvements in symptoms and the quality of life
[5]. In the present case, although BSOmay reduce the decline in the
slope of FEV1, we observed a marked improvement in the patient's
dyspnea and pulmonary function (FEV1) following the initiation of
treatment with sirolimus. The efﬁcacy of sirolimus was further
conﬁrmed by the worsening of symptoms and decline in the pul-
monary function observed during the transient cessation of siroli-
mus therapy.
Adverse reactions during sirolimus treatment include liver
dysfunction and interstitial pneumonia. We observed mild liver
dysfunction that was improved by the transient cessation of siro-
limus and subsequently efﬁciently prevented with dose reduction.
Elevation of the serum KL-6 level, a marker of interstitial pneu-
monia, was also observed in association with the initial dose of
sirolimus. Although we suspected sirolimus-induced interstitial
pneumonia, the chest CT ﬁndings revealed improvements in
reticular opacity and lymphatic edema, and no abnormal ﬁndings
consistent with interstitial pneumonia were observed. The cause of
the KL-6 elevation was unclear.
Due to the absence of clinical manifestations for TSC, the patient
was diagnosed with sporadic LAM. A recent paper demonstrated
that nine of 10 (90%) patients with sporadic LAM were complicated
with uterine LAM based on microscopic examinations, while ﬁve of
eight (63%) patients exhibited adnexal LAM cell inﬁltration [12].
However, the presence of large uterine LAM on a detailed histo-
pathological examination has not been previously reported. The
histopathological ﬁndings demonstrated that uterine and retro-
peritoneal lesions were composed of spindle-shaped cells corre-
sponding to LAM cells. Furthermore, LAM cell clusters enveloped by
D2-40 positive lymphatic endothelial cells were present in
lymphatic vessels and LAM cells inﬁltrated into fat tissue withn the patient's symptoms or pulmonary function. Uterine tumor resection concomitant
home oxygen therapy was administered following tumorectomy, and treatment with
troduction of sirolimus treatment. No obvious regrowth of the uterine tumors has since
T. Numata et al. / Respiratory Medicine Case Reports 15 (2015) 71e7676lymphangiogenesis (Fig. 3G, H and I). The slit like lesions composed
of lymphatic vessels were also demonstrated and previous paper
[12] reported that these ﬁndings are characteristic for sporadic
LAM. Accordingly, the histopathological ﬁndings of large uterine
and retroperitoneal tumors in the present case are consistent with
a diagnosis of LAM lesions, which were complicated with sporadic
LAM.
No conventional therapeutic strategies for treating pelvic LAM
tumors have been demonstrated; however, the successful treat-
ment using a combination of surgical resection and an mTOR in-
hibitor observed in this study offers a potentially effective
treatment modality in cases of pulmonary LAM complicated with
extrapulmonary large LAM lesions. In one trial, angiomyolipomas
regrew following the discontinuation of sirolimus in 13 of 18 (72%)
patients [13]. Therefore, we believe that the administration of
maintenance therapy with sirolimus is necessary for disease con-
trol and that the safety and efﬁcacy of sirolimus must be demon-
strated for long-term use.
4. Summary
We experienced a rare case of sporadic LAM complicated with
large uterine and retroperitoneal LAM lesions. Combination treat-
ment consisting of surgical resection and subsequent mTOR inhi-
bition improved the patient's respiratory symptoms without tumor
regrowth.
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